All Articles

Zesty Paws' award-winning diffuser is more than a pet product; it's a signal of a tech-driven shift in the booming pet wellness industry.

Bliss Baby brings its 'spa-level' care to Walmart. We analyze the strategy, from its generational appeal to its high-stakes bet on premiumizing the mass market.

A Florida lender's tech-fueled success reveals a paradigm shift in mortgages, proving the best new business is the business you already have closed.

In a market driven by pet humanization, Carlson Pet Products’ ‘Brand of the Year’ award reveals a winning strategy: durable, affordable innovation over fleeting trends.

The security giant wins "Great Place to Work" again, but in an industry with 89% turnover, can corporate accolades truly reflect the reality on the ground?

Beyond simple automation, banks and retailers are now orchestrating a blended workforce of humans, bots, and AI agents to redefine efficiency and service.

Delcath Systems posts strong revenue and profits, but the real story is its massive investment in expanding its unique liver therapy to fight breast cancer and more.

An award-winning F1 campaign was more than a spectacle. It launched Data Experience Management, a new category aiming to fix the auto industry's fragmented data.

Global tech firm Meta IT rebrands as Insi, targeting North America’s crowded AI and digital market with a unique philosophy-driven approach. Can it succeed?

A stunning quarter for Establishment Labs shows a company moving from high-growth potential to high-growth reality, underpinned by strategic discipline.

A tech firm's $25K grant empowers a biotech startup to tackle agriculture's $100B plastic crisis with innovative, compostable seaweed materials.

Amphenol's stock split and dividend aren't just financial housekeeping. They're a bold signal of confidence in the booming tech hardware market. Here's why.

A new clinical trial is testing a novel oncolytic virus, VCN-01, to break down pancreatic cancer's defenses, a key step toward a pivotal therapy.

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

July saw 4.35 billion robocalls, the highest in a year. Nearly half were scams, signaling a sophisticated assault on consumers and an escalating data war.

With new patents and a $300M war chest, Beren Therapeutics nears an FDA decision for its NPC drug. But can its public benefit model survive the high-risk biotech gauntlet?

As AI both strains and supports the energy grid, EPRI's SAFERai.power initiative unites rivals and regulators to build a common framework for safe deployment.

Australia's top online bookmaker is betting that the key to AI leadership isn't just speed, but control. Its new AI Gateway aims to solve the core challenge of scaling AI in a high-stakes, real-time world.

MetLife's fifth 'Pet Insurance of the Year' award isn't just a trophy. It's a signal of a massive cultural and economic shift in how we care for our pets.

vTv Therapeutics is nearing a critical milestone with its oral drug for Type 1 diabetes. Can it solve a deadly problem while navigating the financial tightrope?